Extracellular signal-regulated kinase 1/2 regulates NAD metabolism during acute kidney injury through microRNA-34a-mediated NAMPT expression
- 23 December 2019
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 77 (18) , 3643-3655
Abstract
Prior studies have established the important role of extracellular signal-regulated kinase 1/2 (ERK1/2) as a mediator of acute kidney injury (AKI). We demonstrated rapid ERK1/2 activation induced renal dysfunction following ischemia/reperfusion (IR)-induced AKI and downregulated the mitochondrial biogenesis (MB) regulator, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) in mice. In this study, ERK1/2 regulation of cellular nicotinamide adenine dinucleotide (NAD) and PGC-1α were explored. Inhibition of ERK1/2 activation during AKI in mice using the MEK1/2 inhibitor, trametinib, attenuated renal cortical oxidized NAD (NAD+) depletion. The rate-limiting NAD biosynthesis salvage enzyme, NAMPT, decreased following AKI, and this decrease was prevented by ERK1/2 inhibition. The microRNA miR34a decreased with the inhibition of ERK1/2, leading to increased NAMPT protein. Mice treated with a miR34a mimic prevented increases in NAMPT protein in the renal cortex in the presence of ERK1/2 inhibition. In addition, ERK1/2 activation increased acetylated PGC-1α, the less active form, whereas inhibition of ERK1/2 activation prevented an increase in acetylated PGC-1α after AKI through SIRT1 and NAD+ attenuation. These results implicate IR-induced ERK1/2 activation as an important contributor to the downregulation of both PGC-1α and NAD+ pathways that ultimately decrease cellular metabolism and renal function. Inhibition of ERK1/2 activation prior to the initiation of IR injury attenuated decreases in PGC-1α and NAD+ and prevented kidney dysfunction.Keywords
Funding Information
- National Institutes of Health National Institute of General Medical Sciences (R01GM084147)
- Biomedical Laboratory Research and Development, VA Office of Research and Development (BX000851)
- National Institute of Diabetes and Digestive and Kidney Diseases (F31DK105782)
This publication has 67 references indexed in Scilit:
- Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibitionJournal of Controlled Release, 2013
- Persistent disruption of mitochondrial homeostasis after acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2012
- Targeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?Pharmacological Reviews, 2012
- Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in MiceCell Metabolism, 2011
- SRT1720 Induces Mitochondrial Biogenesis and Rescues Mitochondrial Function after Oxidant Injury in Renal Proximal Tubule CellsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescenceThe FEBS Journal, 2009
- miR-34a repression of SIRT1 regulates apoptosisProceedings of the National Academy of Sciences, 2008
- Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic EnzymeCell Metabolism, 2007
- A fundamental system of cellular energy homeostasis regulated by PGC-1αProceedings of the National Academy of Sciences, 2007
- Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1αThe EMBO Journal, 2007